Apr 04, 2019 - Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.
Apr 04, 2019 - Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets approval in EU after being approved in the United States last September.
Apr 05, 2019 - Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Apr 10, 2019 - Key highlights of the past week are new drug approvals, collaborations and pipeline updates.
Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Apr 23, 2019 - Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 24, 2019 - Novartis (NVS) beats on Q1 earnings, sales marginally miss estimates.
Apr 24, 2019 - While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Apr 29, 2019 - Cigna's (CI) Q1 earnings should benefit from increase in revenues and membership.
Apr 30, 2019 - AMGN earnings call for the period ending March 31, 2019.